Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials

ClinicalLIVEUpdated 18 Nov 2026

New Clinical Trials

Clinical trials companies registered in the last 30 days, worldwide, with the sponsor, phase and countries.

Sources: ClinicalTrials.gov · Rebuilt weekly · Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase.

Trials
777
in the 30 days to 2026-11-18
Added in 30 days
777
to 18 Nov 2026
Top country
United States
192 · 25% of the list
Phase covered
8
distinct values
Snapshot · 18 Nov 2026
Explore all 777

Signals

What the register says this week, and why it matters if you sell into it.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
  3. 174 of the listed studies are device, diagnostic or digital-health studies (no drug phase).
  4. A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

Export the full new clinical trials

777 rows as a .csv. Free. Every field, with its source link.

Country 1
Phase
Study type
171 / 777 trials
PostedSponsorStudyPhaseStatus
18 Nov 2026Beijing Baheal Wisart Medical Research Co., LtdChinaSafety, Tolerability, and Pharmacokinetic Study of Single and Multiple Ascending Dose of YY524051 Tablets in Healthy Adults.Phase 1Not Yet Recruiting18 Nov 2026Beijing Xunsheng Biomedical Research Co., Ltd.ChinaSafety, Tolerability, and Efficacy of a Therapeutic Intervention for HPV16/18 InfectionNot applicableRecruiting18 Nov 2026CASI pharmaceuticals, Inc.ChinaA Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune ThrombocytopeniaPhase 2Not Yet Recruiting18 Nov 2026Eli Lilly and CompanyChinaA Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy ParticipantsPhase 1Not Yet Recruiting18 Nov 2026Fujian Akeylink Biotechnology Co., Ltd.ChinaA Study on the Pharmacokinetics and Safety of GST-HG141 Tablets in Participants With Hepatic Impairment and Normal Liver FunctionPhase 1Recruiting18 Nov 2026Gan & Lee Pharmaceuticals.ChinaA Pharmacokinetics Study of GZR33 Injection at Different Injection SitesPhase 1Not Yet Recruiting18 Nov 2026Longbio PharmaChinaA Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 AntihistaminesPhase 3Not Yet Recruiting18 Nov 2026Shanghai Henlius BiotechAustralia, ChinaA Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid TumorsPhase 1Not Yet Recruiting18 Nov 2026Xiamen Amoytop Biotech Co., Ltd.ChinaPhase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis BPhase 1Not Yet Recruiting18 Nov 2026Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.ChinaDiagnostic Performance and Safety of Ragweed Pollen and Dog Dander Skin Prick Test SolutionsPhase 3Not Yet Recruiting17 Nov 2026AstraZenecaUnited States, Argentina, AustraliaA Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLCPhase 2Not Yet Recruiting17 Nov 2026Beijing Xunsheng Biomedical Research Co., Ltd.ChinaAVL-102 for the Treatment of HPV 16/18/52/58-Related High-Grade LesionsPhase 1Recruiting17 Nov 2026CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.ChinaA Study of SYH2053 Injection in Participants With Hepatic Impairment Compared to Participants With Normal Hepatic FunctionPhase 1Recruiting17 Nov 2026GenAns Biotechnology Co., LtdChinaGA001 Injection in Retinitis PigmentosaPhase 2Not Yet Recruiting17 Nov 2026Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.ChinaA Study of HW201877 Capsules for Participants With Moderate to Severe Active Inflammatory Bowel Disease (IBD)Phase 2Not Yet Recruiting17 Nov 2026Innatus Therapeutics (Shanghai) Co., Ltd.ChinaA Phase I Study of INT-1868 Tablets in Healthy Adult Participants (INT-1868-I101)Phase 1Not Yet Recruiting17 Nov 2026Nakhia Impex LLCChina35-kDa Hyaluronan Fragment (HA35) Chewable Tablets for Gingival Inflammation, Oral Pain and Pharyngeal DiscomfortNot applicableNot Yet Recruiting17 Nov 2026Nakhia Impex LLCChina10% 35-kDa Hyaluronan Fragment (HA35) Gel for Periocular Comfort and AestheticsNot applicableNot Yet Recruiting17 Nov 2026Reinovax Biologics Co., LTDChinaA Phase Ⅲ Clinical Trial of an Investigative 24-valent Pneumococcal Polysaccharide Conjugate VaccinePhase 3Not Yet Recruiting17 Nov 2026Reistone Biopharma Company LimitedChinaA Study of RSS0343 Tablets in Healthy Participants and in Participants With Mild or Moderate Renal ImpairmentPhase 1Not Yet Recruiting17 Nov 2026Tasly Biopharmaceuticals Co., Ltd.ChinaIntravenous Recombinant Human Prourokinase (rhPro-UK) for Acute Ischemic Stroke Within 4.5 to 24 Hours of OnsetPhase 3Not Yet Recruiting16 Nov 2026AkesoChinaA Study of AK158D1 in Advanced Solid TumorsPhase 1Not Yet Recruiting16 Nov 2026Beijing Jiake Ruikang Pharmaceutical Technology Co., Ltd.ChinaSafety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of JAR-2203 in Healthy Participants With Elevated Plasma Lipoprotein(a)Phase 1Recruiting16 Nov 2026Chendu DIAO Pharmaceutical Group CO., LTD.ChinaPharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Varying Degrees of Renal Impairment and Normal Renal FunctionPhase 1Recruiting16 Nov 2026Chengdu Suncadia Medicine Co., Ltd.ChinaA Study of HRS-8046 in Patients With Advanced Solid Tumors: Safety, Tolerability, and PharmacokineticsPhase 1Not Yet Recruiting16 Nov 2026Chengdu Suncadia Medicine Co., Ltd.ChinaA Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-9308 Tablet as Monotherapy or Combination Therapy in Participants With Advanced Solid TumorsPhase 1, Phase 2Not Yet Recruiting16 Nov 2026ChinaNormChinaDevice Impact on the Efficacy of Serum Product StudyNot applicableRecruiting16 Nov 2026CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.ChinaA Study of SYH2053 Injection in Participants With Renal Impairment Compared to Participants With Normal Renal FunctionPhase 1Recruiting16 Nov 2026CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.ChinaSYH2062 Injection in Participants With Mild to Moderate Essential Hypertension .Phase 2Recruiting16 Nov 2026CStone PharmaceuticalsAustralia, ChinaA First-in-human (FIH), Open-label, and Multi-center Study of CS5006 in Participants With Advanced Solid TumorsPhase 1, Phase 2Not Yet Recruiting16 Nov 2026DiproBio (Shanghai) Co., Ltd.ChinaEffects of Bifidobacterium Longum Subsp. Infantis i18 on Gut Microbiota Development and Health in Early LifeNot applicableNot Yet Recruiting16 Nov 2026DiproBio (Shanghai) Co., Ltd.ChinaEffects of a Combination of Bifidobacterium Longum Subsp. Longum Strains on Stress and Related Health Outcomes in Young AdultNot applicableNot Yet Recruiting16 Nov 2026Kanglin Biotechnology (Hangzhou) Co., Ltd.ChinaGene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical StudyPhase 1, Phase 2Not Yet Recruiting16 Nov 2026Nanjing Immunophage Biotech Co., LtdChinaA Study of IPG11406 Tablets in Participants With Lupus NephritisPhase 2Not Yet Recruiting16 Nov 2026Shanghai Mabgeek Biotech.Co.LtdChinaMG-K10 in Pediatric Atopic Dermatitis (6-12 Years)Phase 1, Phase 2Not Yet Recruiting13 Nov 2026Changchun GeneScience Pharmaceutical Co., Ltd.ChinaClinical Trial of GenSci136 in Patients With Myasthenia GravisPhase 1, Phase 2Not Yet Recruiting13 Nov 2026Hangzhou Sciwind Biosciences Co., Ltd.ChinaA Phase I Study to Evaluate the Food Effect on Ecnoglutide TabletPhase 1Not Yet Recruiting13 Nov 2026Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.ChinaPhase I Study of HW281171 Tablets in Healthy ParticipantsPhase 1Not Yet Recruiting13 Nov 2026Nanjing Immunophage Biotech Co., LtdChinaStudy of IPG1094 Tablets in Chinese Healthy Adults and Obese AdultsPhase 1Not Yet Recruiting13 Nov 2026RemeGen Co., Ltd.ChinaRC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ AdenocarcinomaPhase 2, Phase 3Not Yet Recruiting13 Nov 2026RemeGen Co., Ltd.ChinaIIIb Trial for RC28-E Injection in Participants With DME and wAMDPhase 3Not Yet Recruiting13 Nov 2026Shanghai Henlius BiotechAustralia, ChinaA Phase I Study of HLX109 in Healthy ParticipantsPhase 1Not Yet Recruiting13 Nov 2026Suzhou Siran Biotechnology Co.,Ltd.ChinaSA030 Injection in Healthy ParticipantsPhase 1Not Yet Recruiting13 Nov 2026Suzhou Zenith Vascular SciTech LimitedChinaSingle-Arm Trial of Carotid Stenting for Carotid Stenosis (Timing Trial)Not applicableNot Yet Recruiting13 Nov 2026Zhuhai Hengqin ImStem Biotechnology Co., Ltd.ChinaA Study of IMS001 in Patients With Multiple SclerosisPhase 1Recruiting12 Nov 2026AstraZenecaChina, Hong Kong, MalaysiaA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve PatientsPhase 3Not Yet Recruiting12 Nov 2026Beijing VDJBio Co., LTD.ChinaPhase I Trial of Subcutaneous VDJ010 In Healthy Subjects and Patients With Ulcerative ColitisPhase 1Recruiting12 Nov 2026Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.ChinaClinical Study of YKYY013 Injection in HBeAg-negative Chronic Hepatitis B Virus-infected Patients Treated With Nucleos(t)Ide AnaloguesPhase 2Not Yet Recruiting12 Nov 2026CSPC-NBP Pharmaceutical Co., Ltd.ChinaA Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to Evaluate the Efficacy and Safety of SYH9061 in Adult Patients With Idiopathic Pulmonary FibrosisPhase 2Not Yet Recruiting12 Nov 2026Hangzhou DAC Biotechnology Co., Ltd.ChinaA Study of DXC016 in Patients With Advanced Solid Tumors.Phase 1Not Yet Recruiting

// How AOS uses this

Every row here is a potential account. AOS finds the ones that need what you sell, maps the decision makers and prepares the outreach for your approval.